Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
Iron deficiency is prevalent in heart transplant recipients, and may be associated with
reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous
iron isomaltoside on exercise capacity, muscle strength, cognition and quality of life in
iron-deficient heart transplant recipients